[1] Chang Y, Ryu S, Sung KC, et al. Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung health study. Gut, 2019, 68(9): 1667-1675.
[2] You M, Jogasuria A, Lee K, et al. Signal transduction mechanisms of alcoholic fatty liver disease: Emer Ging role of lipin-1. Curr Mol Pharmacol, 2017, 10(3): 226-236.
[3] Hsu JY, Lin HH, Hsu CC, et al. Aqueous extract of pepino (solanum muriactum ait) leaves ameliorate lipid accumulation and oxidative stress in alcoholic fatty liver disease. Nutrients, 2018, 10(7): 931-932.
[4] Jeong JY, Sohn JH, Baek YH, et al. New botanical drug, hl tablet, reduces hepatic fat as measured by magnetic resonance spectroscopy in patients with nonalcoholic fatty liver disease: a placebo-controlled, randomized, phase ii trial. World J Gastroenterol, 2017, 23(32): 5977-5985.
[5] 李笠, 梁学亚. 水飞蓟宾葡甲胺联合多烯磷脂酰胆碱治疗酒精性肝炎患者初步临床研究. 实用肝脏病杂志, 2017, 20(4): 412-415.
[6] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.酒精性肝病防治指南(2018年更新版).实用肝脏病杂志,2018,21(2): 170-176.
[7] Ahn JM, Paik YH, Min SY, et al. Relationship between controlled attenuation parameter and hepatic steatosis as assessed by ultrasound in alcoholic or nonalcoholic fatty liver disease. Gut Liver, 2016, 10(2): 295-302.
[8] Chen X, Ward SC, Cederbaum AI, et al. Alcoholic fatty liver is enhanced in cyp2a5 knockout mice: the role of the pparα-fgf21 axis. Toxicology, 2017, 379(10): 12-21.
[9] Wong T, Dang K, Ladhani S, et al. Prevalence of alcoholic fatty liver disease among adults in the United States. JAMA, 2019, 321(17): 1723-1725.
[10] Abenavoli L, Izzo AA, Mili N, et al. Milk thistle (silybum marianum): a concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. Phytother Res, 2018, 32(11): 2202-2213.
[11] 杜卫星, 叶青, 李金科, 等. 胆宁片联合瑞舒伐他汀治疗非酒精性脂肪性肝病患者HOMA-IR和血清TNF-α水平变化. 实用肝脏病杂志, 2017, 20(4): 490-491.
[12] Federico A, Dallio M, Loguercio C, et al. Silymarin/silybin and chronic liver disease: a marriage of many years. Molecules, 2017, 22(2): 11-12.
[13] Vecchione G, Grasselli E, Cioffi F, et al. The nutraceutic silybin counteracts excess lipid accumulation and ongoing oxidative stress in an in vitro model of non-alcoholic fatty liver disease progression. Front Nutr, 2017, 49(1): 41-42.
[14] 赵文霞, 张丽慧. 合理应用中成药治疗非酒精性脂肪性肝病. 实用肝脏病杂志, 2017, 20(2): 132-134.
[15] Zhang B, Xu D, She L, et al. Silybin inhibits nlrp3 inflammasome assembly through the nad+/sirt2 pathway in mice with nonalcoholic fatty liver disease. FASEB J, 2018, 32(2): 757-767.
[16] Wang Y, Wu T, Hu D, et al. Intracellular hepatitis b virus increases hepatic cholesterol deposition in alcoholic fatty liver via hepatitis b core protein. J Lipid Res, 2018, 59(1): 58-68.
[17] Cui CX, Deng JN, Yan L, et al.Silibinin capsules improves high fat diet-induced nonalcoholic fatty liver disease in hamsters through modifying hepatic de novo lipogenesis and fatty acid oxidation. J Ethnopharmacol, 2017, 208(17): 24-35.
[18] 范建高, 徐正婕, 丁晓东, 等. 胆宁片对高脂饮食大鼠非酒精性脂肪性肝炎模型形成的影响. 实用肝脏病杂志, 2018, 10(3): 23-25.
[19] Abenavoli L, Greco M, Nazionale I, et al. Effects of mediterranean diet supplemented with silybin-vitamin e-phospholipid complex in overweight patients with non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol, 2015, 9(4): 519-527.
[20] Tu LN, Showalter MR, Cajka T, et al. Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice. Sci Rep, 2017, 7(1): 6118-6120. |